- Home
- SKYH vs PBYI Comparison
SKYH vs PBYI Comparison
Compare SKYH & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYH | PBYI |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYH | PBYI |
|---|---|---|
| Price | $8.82 | $5.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $13.83 | $7.00 |
| AVG Volume (30 Days) | 128.9K | ★ 380.6K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | $24,125,000.00 | ★ $211,995,000.00 |
| Revenue This Year | $95.79 | N/A |
| Revenue Next Year | $69.76 | N/A |
| P/E Ratio | ★ N/A | $7.99 |
| Revenue Growth | ★ 95.23 | N/A |
| 52 Week Low | $8.22 | $2.58 |
| 52 Week High | $14.20 | $6.27 |
Technical Indicators
Market Signals| Indicator | SKYH | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 52.04 |
| Support Level | $8.49 | $5.81 |
| Resistance Level | $9.23 | $6.27 |
| Average True Range (ATR) | 0.32 | 0.24 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 23.42 | 26.58 |
Price Performance
Historical ComparisonAbout SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.